Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 830

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 5
Chunk 830
---
appointing
or replacing the independent registered public accounting firm;

26

●determining
the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements
between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report
or related work;

●establishing
procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or
reports which raise material issues regarding our financial statements or accounting policies;

●monitoring
compliance on a quarterly basis and, if any non-compliance is identified, immediately taking all action necessary to rectify such non-compliance
or otherwise causing compliance; and

●reviewing
and approving all payments made to our existing shareholders, executive officers or directors and their respective affiliates. Any payments
made to members of our audit committee will be reviewed and approved by our board of directors, with the interested director or directors
abstaining from such review and approval.

Compensation
Committee Interlocks and Insider Participation

None
of our executive officers currently serves, and in the past year has not served, as a member of the compensation committee of any entity
that has one or more executive officers serving on our board of directors.

Code
of Ethics

We
have adopted a Code of Ethics applicable to our directors, officers and employees. A copy of the Code of Ethics will be provided without
charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current
Report on Form 8-K.

Trading
Policies

The
Company has adopted an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by our directors,
officers and employees. A copy of our insider trading policy is filed as Exhibit 19.1 to this Annual Report on Form 10-K for the fiscal
year ended December 31, 2024. In addition, with regard to the Company’s trading in its own securities, it is the Company’s
policy to comply with the federal securities laws and the applicable exchange listing requirements.

Availability
of Documents

We
have filed a copy of our Code of Ethics and our audit committee charter as exhibits to the registration statement relating to our IPO.
You can review these documents by accessing our public filings at the SEC’s website at www.sec.gov. We intend to disclose any amendments
to or waivers of certain provisions of our Code of Ethics in a Current Report on